These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8395157)

  • 41. Asymptomatic Lambert-Eaton syndrome.
    Denys EH; Lennon VA
    Muscle Nerve; 2014 May; 49(5):764-7. PubMed ID: 24259319
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An autoimmune channelopathy associated with cancer: Lambert-Eaton myasthenic syndrome.
    Takamori M
    Intern Med; 1999 Feb; 38(2):86-96. PubMed ID: 10225662
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Lambert-Eaton myasthenic syndrome and myasthenia gravis].
    Takamori M; Iwasa K; Komai K; Yasukawa Y
    No To Shinkei; 1997 Dec; 49(12):1089-100. PubMed ID: 9453039
    [No Abstract]   [Full Text] [Related]  

  • 44. Synaptotagmin can cause an immune-mediated model of Lambert-Eaton myasthenic syndrome in rats.
    Takamori M; Hamada T; Komai K; Takahashi M; Yoshida A
    Ann Neurol; 1994 Jan; 35(1):74-80. PubMed ID: 8285596
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lambert-Eaton myasthenic syndrome following H1N1-influenza vaccination: a case report.
    Ansakorpi H; Rusanen H; Rytky S; Färkkilä M
    Acta Neurol Scand; 2012 Nov; 126(5):e25-8. PubMed ID: 22571392
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Anti-voltage-gated calcium channel antibodies in the Lambert-Eaton myasthenic syndrome].
    Motomura M; Suenaga A; Matsuo H; Tsujihata M; Nagataki S
    Rinsho Shinkeigaku; 1994 Oct; 34(10):980-4. PubMed ID: 7834958
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anesthesia for an unsuspected Lambert-Eaton myasthenic syndrome with autoantibodies and occult small cell lung carcinoma.
    Small S; Ali HH; Lennon VA; Brown RH; Carr DB; de Armendi A
    Anesthesiology; 1992 Jan; 76(1):142-5. PubMed ID: 1309626
    [No Abstract]   [Full Text] [Related]  

  • 48. Acetylcholine receptor antibodies in the Lambert-Eaton myasthenic syndrome.
    Katz JS; Wolfe GI; Bryan WW; Tintner R; Barohn RJ
    Neurology; 1998 Feb; 50(2):470-5. PubMed ID: 9484374
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lambert-Eaton myasthenic syndrome without anti-calcium channel antibody: adverse effect of calcium antagonist diltiazem.
    Ueno S; Hara Y
    J Neurol Neurosurg Psychiatry; 1992 May; 55(5):409-10. PubMed ID: 1318359
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Lambert-Eaton myasthenic syndrome (LEMS)].
    Fukumoto S; Motomura M
    Nihon Rinsho; 2015 Sep; 73 Suppl 7():793-800. PubMed ID: 26480796
    [No Abstract]   [Full Text] [Related]  

  • 51. Transient neonatal Lambert-Eaton syndrome.
    Reuner U; Kamin G; Ramantani G; Reichmann H; Dinger J
    J Neurol; 2008 Nov; 255(11):1827-8. PubMed ID: 18758885
    [No Abstract]   [Full Text] [Related]  

  • 52. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome.
    Bain PG; Motomura M; Newsom-Davis J; Misbah SA; Chapel HM; Lee ML; Vincent A; Lang B
    Neurology; 1996 Sep; 47(3):678-83. PubMed ID: 8797464
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phoneutria nigriventer omega-Phonetoxin IIA: a new tool for anti-calcium channel autoantibody assays in Lambert-Eaton myasthenic syndrome.
    Martin-Moutot N; Haro Ld; Santos RG; Mori Y; Seagar M
    Neurobiol Dis; 2006 Apr; 22(1):57-63. PubMed ID: 16289869
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pathogenic autoantibodies in the lambert-eaton myasthenic syndrome.
    Lang B; Pinto A; Giovannini F; Newsom-Davis J; Vincent A
    Ann N Y Acad Sci; 2003 Sep; 998():187-95. PubMed ID: 14592874
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Myasthenia gravis and myasthenic syndrome.
    Antozzi C
    Neurol Sci; 2003 Oct; 24 Suppl 4():S260-3. PubMed ID: 14598056
    [TBL] [Abstract][Full Text] [Related]  

  • 56. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome.
    Sabater L; Titulaer M; Saiz A; Verschuuren J; Güre AO; Graus F
    Neurology; 2008 Mar; 70(12):924-8. PubMed ID: 18032743
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pathogenic autoantibodies to neuronal proteins in neurological disorders.
    Vincent A; Lily O; Palace J
    J Neuroimmunol; 1999 Dec; 100(1-2):169-80. PubMed ID: 10695727
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Human autoantibodies specific for the alpha1A calcium channel subunit reduce both P-type and Q-type calcium currents in cerebellar neurons.
    Pinto A; Gillard S; Moss F; Whyte K; Brust P; Williams M; Stauderman K; Harpold M; Lang B; Newsom-Davis J; Bleakman D; Lodge D; Boot J
    Proc Natl Acad Sci U S A; 1998 Jul; 95(14):8328-33. PubMed ID: 9653186
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antibodies to synthetic peptides of the alpha1A subunit of the voltage-gated calcium channel in Lambert-Eaton myasthenic syndrome.
    Takamori M; Iwasa K; Komai K
    Neurology; 1997 May; 48(5):1261-5. PubMed ID: 9153453
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Specificity of Lambert-Eaton myasthenic syndrome immunoglobulin for nerve terminal calcium channels.
    Hewett SJ; Atchison WD
    Brain Res; 1992 Dec; 599(2):324-32. PubMed ID: 1363289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.